CGS.ASX: Cogstate 3Q26 Business Update

Cogstate 3Q26 Business Update

Stock	Cogstate Ltd (CGS.ASX)
Release Time	8 Apr 2026, 8:21 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Cogstate Reports Strong 3Q26 Business Update

Key Points

Sales contracts executed during 3Q26 totalled $25.4 million
Total contracted revenue for FY26 increased to $56.0 million
Contracted revenue for FY27 increased to $35.6 million

Full Summary

Cogstate Ltd (ASX:CGS), a global leader in clinical trial endpoint data quality and digital cognitive assessments, today releases a business update for the quarter ended 31 March 2026 ('3Q26'). Cogstate continues to demonstrate strong demand across an expanding range of Central Nervous System (CNS) indications, consistent with trends outlined with the release of the 1H26 financial results. Sales contracts executed during 3Q26 totalled $25.4 million, bringing the total value executed over the 9 months to 31 March 2026 to $67.1 million. Contracted revenue for the June 2026 half year (2H26), including revenue recognised during 3Q26, is $29.1 million, up from $21.7 million under contract at 31-Dec-25. This brings full year FY26 revenue under contract (including first half actual of $26.9 million) to $56.0 million (FY25 total revenue was $53.1 million). Contracted revenue for next financial year (FY27) is $35.6 million, up from $27.0 million under contract at 31-Dec-25.

Guidance

Full year FY26 revenue under contract is $56.0 million, up from FY25 total revenue of $53.1 million. Contracted revenue for next financial year (FY27) is $35.6 million.